Bangkok--Mar 20--BLH
Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy
Objective
The objective of the COMPACT study was to determine and compare the effect of adding montelukast to inhaled budesonide 800 mg daily vs. doubling the dose of budesonide from 800 mg to 1600 mg daily.
Study Design
Double-blind, randomized, parallel-group, non-inferiority, multicenter, 16-week study comparing the clinical benefits of adding montelukast to budesonide compared with doubling the budesonide dose in adults with asthma.
During a one-month run-in period, all patients were given 800 Tg (200 Tg, 2 puffs, twice daily) of budesonide via Turbuhalerไ and a montelukast placebo once daily.
After the run-in period, patients were randomized to receive montelukast 10 mg and budesonide 800 Tg daily (n=448) or budesonide 1600 Tg (n=441) and montelukast placebo daily for an additional 12 weeks.
Inclusion Criteria
Adult asthma patients, ages 15-75, who were uncontrolled on inhaled corticosteroids alone, had a forced expiratory volume in one second (FEV1) of ณ 50 percent predicted and a ณ 12 percent increase in FEV1 after short-acting J-agonist administration.
Study Centres
21 centres with 889 total patients across 24 countries.
Primary Endpoint
Improvement in morning peak expiratory flow (PEF).
Secondary Endpoints
Onset of action, improvement in asthma-free days, nocturnal awakenings, asthma exacerbations, daytime symptoms, beta-agonist use, blood eosinophils, asthma specific quality of life and resource utilization.
Findings
Both patient groups' asthma improved during the course of the study, but the group using montelukast saw improvement faster. AM PEF - the primary endpoint -- improved in both groups continually throughout the study.
Primary Endpoint
Patients in both groups demonstrated similar improvements in morning PEF. Morning PEF increased by 33.3 liters per minute (LPM) in the montelukast/budesonide 800 Tg group, and by 29.9 LPM in the budesonide 1600 Tg /placebo group.
Secondary Endpoints
Therapy with montelukast and budesonide showed a faster onset of action in morning PEF (as early as day one) versus the double dose of budesonide as demonstrated through a change from baseline (20.1 versus 9.6 L/min, respectively, p